Cathay Biotech Inc

Synthetic Biology (non-pharma)▲4

Cathay Biotech first-half net profit 372 million yuan, up 20.75% year on year

Cathay Biotech disclosed its 2026 semi-annual report. In the first half, it achieved operating revenue of 1.9 billion yuan, up 13.73% year on year, and net profit attributable to shareholders of the listed company of 372 million yuan, up 20.75% year on year. The profit growth was mainly driven by continued volume expansion of long-chain dibasic acids and revenue contribution from new product sales. During the reporting period, bio-based sebacic acid and bio-based piperidine continued to be introduced to the market, bio-based azelaic acid entered the customer sampling stage, and long-chain polyamide modified products achieved large-scale sales. The company also led an investment in and increased its stake in the AI protein design company MoleculeMind, and currently holds about 17.43% of its shares, making it the largest external shareholder. At the same time, its self-built high-throughput research and development platform has entered the commissioning stage.

688065.CG ▲

Synthetic Biology (non-pharma) ▲

上海证券报·7dRead more ▾

Critical Materials & Supply Chain▲

Chemical ETF Penghua Sees Net Subscription of 91 Million Units Today; Over 60% of Shenzhen-Listed Chemical Companies Report Expected Profit Growth

Chemical ETF Penghua recorded net subscriptions of 91 million units today, with the latest price at 0.74 yuan. In related news, 94 chemical companies listed in Shenzhen have disclosed their semi-annual earnings forecasts for 2026. Over 60% are profitable and expect year-on-year profit growth. Among them, 46 companies anticipate profit growth exceeding 50%, and 10 expect to turn losses into gains. China Securities believes that low downstream inventories combined with the approaching traditional peak season could unleash restocking demand. Meanwhile, the carbon peak action plan is driving green transformation in the industry, opening growth windows for phosphorus-based new materials and electronic-grade phosphoric acid. As of the close on July 20, the CSI Sub-Industry Chemical Theme Index edged up 0.01%. Constituent stock Baofeng Energy rose 9.30%, and Cathay Biotech gained 8.28%.

600989.CG ▲688065.CG ▲

Critical Materials & Supply Chain ▲

Jiemian·38dRead more ▾

Semiconductors▼

Maxio Technology Forecasts 821% First-Half Net Profit Surge; Cathay Biotech Files Trade Secret Lawsuit

Maxio Technology expects net profit attributable to the parent company of approximately 517 million yuan in the first half of 2026, a year-on-year increase of around 821 percent, mainly driven by growing demand in the storage market and a steady rise in shipments of its PCIe series controller chips. Cathay Biotech and its subsidiaries have filed a lawsuit with the Beijing High People's Court against ten defendants, including Wang Zhizhou and Shandong Hanlin Biotechnology, for infringement of trade secrets, seeking economic damages of about 967 million yuan and reasonable expenses of 1 million yuan. The case has been accepted. XTC New Energy Materials released a preliminary earnings report, with first-half 2026 revenue of 14.488 billion yuan, up 91.09 percent year-on-year, and net profit attributable to the parent company of 491 million yuan, up 46.62 percent. In addition, Deep Principle completed a Series A3 funding round of nearly 1 billion yuan, Moji Technology completed a combined Series A and A+ funding round of 600 million yuan, and Magic Code Leap completed a seed funding round of tens of millions of yuan.

688065.CG ▼688449.CG ▲688778.CG ▲

Semiconductors

科创板日报·44dRead more ▾